Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.

Autor: Rey-Ares L; Pfizer SRL, Villa Adelina, Argentina. Electronic address: lucila.reyares@pfizer.com., Ta A; Cytel, United Kingdom., Freigofaite D; Cytel, Netherlands., Warren S; Global Health Economics & Outcomes Research, Pfizer Inc, New York, NY, United States., Mac Mullen M; Pfizer SRL, Villa Adelina, Argentina., Carballo C; Pfizer SRL, Villa Adelina, Argentina., Huang L; Global Health Economics & Outcomes Research, Pfizer Inc, Collegeville, PA, United States.

Publikováno v: Vaccine [Vaccine] 2024 Oct 03; Vol. 42 (23), pp. 126043. Date of Electronic Publication: 2024 Jun 15.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

EE47 Micro-Costing of Hematopoietic Cell Transplantation, Graft-Versus-Host Disease and Veno-Occlusive Disease Associated with the Treatment of Acute Myeloid Leukemia in Argentina

Autor: Gonzalez, L, Malacalza, J, Mac Mullen, M, Seyahian, E, Macadam, P, Jorgensen, N

Publikováno v: In Value in Health December 2022 25(12) Supplement:S62-S62

POSA198 Clinical and Economic Burden Attributable to Serotypes Included in Current and Future Pneumococcal Conjugate Vaccines in Argentinean Children Under Five Years of Age

Autor: Mac Mullen, M, Abalos, G, Carballo, C, Perdrizet, J, Horn, E

Publikováno v: In Value in Health January 2022 25(1) Supplement:S125-S125

PIN47 Cost-Effectiveness Analysis Ceftazidime/Avibactam for the Treatment of Hospital Acquired Pneumonia and Ventilator Associated Pneumonia Due to Carbapenem Resistant Klebsiella Pneumonia in Argentina

Autor: Mac Mullen, M., Pein, C.

Publikováno v: In Value in Health December 2020 23 Supplement 2:S552-S552